File Download

There are no files associated with this item.

  Links for fulltext
     (May Require Subscription)
Supplementary

Article: Intranasal influenza-vectored COVID-19 vaccine restrains the SARS-CoV-2 inflammatory response in hamsters

TitleIntranasal influenza-vectored COVID-19 vaccine restrains the SARS-CoV-2 inflammatory response in hamsters
Authors
Issue Date11-Jul-2023
PublisherNature Research
Citation
Nature Communications, 2023, v. 14, n. 1 How to Cite?
Abstract

The emergence of severe acute respiratory syndrome coronavirus-2 (SARS-CoV-2) variants and "anatomical escape" characteristics threaten the effectiveness of current coronavirus disease 2019 (COVID-19) vaccines. There is an urgent need to understand the immunological mechanism of broad-spectrum respiratory tract protection to guide broader vaccines development. Here we investigate immune responses induced by an NS1-deleted influenza virus vectored intranasal COVID-19 vaccine (dNS1-RBD) which provides broad-spectrum protection against SARS-CoV-2 variants in hamsters. Intranasal delivery of dNS1-RBD induces innate immunity, trained immunity and tissue-resident memory T cells covering the upper and lower respiratory tract. It restrains the inflammatory response by suppressing early phase viral load post SARS-CoV-2 challenge and attenuating pro-inflammatory cytokine (Il6, Il1b, and Ifng) levels, thereby reducing excess immune-induced tissue injury compared with the control group. By inducing local cellular immunity and trained immunity, intranasal delivery of NS1-deleted influenza virus vectored vaccine represents a broad-spectrum COVID-19 vaccine strategy to reduce disease burden.


Persistent Identifierhttp://hdl.handle.net/10722/337885
ISSN
2023 Impact Factor: 14.7
2023 SCImago Journal Rankings: 4.887
ISI Accession Number ID

 

DC FieldValueLanguage
dc.contributor.authorZhang, Liang-
dc.contributor.authorJiang, Yao-
dc.contributor.authorHe, Jinhang-
dc.contributor.authorChen, Junyu-
dc.contributor.authorQi, Ruoyao-
dc.contributor.authorYuan, Lunzhi-
dc.contributor.authorShao, Tiange-
dc.contributor.authorZhao, Hui-
dc.contributor.authorChen, Congjie-
dc.contributor.authorChen, Yaode-
dc.contributor.authorWang, Xijing-
dc.contributor.authorLei, Xing-
dc.contributor.authorGao, Qingxiang-
dc.contributor.authorZhuang, Chunlan-
dc.contributor.authorZhou, Ming-
dc.contributor.authorMa, Jian-
dc.contributor.authorLiu, Wei-
dc.contributor.authorYang, Man-
dc.contributor.authorFu, Rao-
dc.contributor.authorWu, Yangtao-
dc.contributor.authorChen, Feng-
dc.contributor.authorXiong, Hualong-
dc.contributor.authorNie, Meifeng-
dc.contributor.authorChen, Yiyi-
dc.contributor.authorWu, Kun-
dc.contributor.authorFang, Mujin-
dc.contributor.authorWang, Yingbin-
dc.contributor.authorZheng, Zizheng-
dc.contributor.authorHuang, Shoujie-
dc.contributor.authorGe, Shengxiang-
dc.contributor.authorCheng, Shih Chin-
dc.contributor.authorZhu, Huachen-
dc.contributor.authorCheng, Tong-
dc.contributor.authorYuan, Quan-
dc.contributor.authorWu, Ting-
dc.contributor.authorZhang, Jun-
dc.contributor.authorChen, Yixin-
dc.contributor.authorZhang, Tianying-
dc.contributor.authorLi, Changgui-
dc.contributor.authorQi, Hai-
dc.contributor.authorGuan, Yi-
dc.contributor.authorXia, Ningshao-
dc.date.accessioned2024-03-11T10:24:38Z-
dc.date.available2024-03-11T10:24:38Z-
dc.date.issued2023-07-11-
dc.identifier.citationNature Communications, 2023, v. 14, n. 1-
dc.identifier.issn2041-1723-
dc.identifier.urihttp://hdl.handle.net/10722/337885-
dc.description.abstract<p>The emergence of severe acute respiratory syndrome coronavirus-2 (SARS-CoV-2) variants and "anatomical escape" characteristics threaten the effectiveness of current coronavirus disease 2019 (COVID-19) vaccines. There is an urgent need to understand the immunological mechanism of broad-spectrum respiratory tract protection to guide broader vaccines development. Here we investigate immune responses induced by an NS1-deleted influenza virus vectored intranasal COVID-19 vaccine (dNS1-RBD) which provides broad-spectrum protection against SARS-CoV-2 variants in hamsters. Intranasal delivery of dNS1-RBD induces innate immunity, trained immunity and tissue-resident memory T cells covering the upper and lower respiratory tract. It restrains the inflammatory response by suppressing early phase viral load post SARS-CoV-2 challenge and attenuating pro-inflammatory cytokine (Il6, Il1b, and Ifng) levels, thereby reducing excess immune-induced tissue injury compared with the control group. By inducing local cellular immunity and trained immunity, intranasal delivery of NS1-deleted influenza virus vectored vaccine represents a broad-spectrum COVID-19 vaccine strategy to reduce disease burden.<br></p>-
dc.languageeng-
dc.publisherNature Research-
dc.relation.ispartofNature Communications-
dc.rightsThis work is licensed under a Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International License.-
dc.titleIntranasal influenza-vectored COVID-19 vaccine restrains the SARS-CoV-2 inflammatory response in hamsters-
dc.typeArticle-
dc.identifier.doi10.1038/s41467-023-39560-9-
dc.identifier.scopuseid_2-s2.0-85164421290-
dc.identifier.volume14-
dc.identifier.issue1-
dc.identifier.eissn2041-1723-
dc.identifier.isiWOS:001037937100018-
dc.identifier.issnl2041-1723-

Export via OAI-PMH Interface in XML Formats


OR


Export to Other Non-XML Formats